Edgewise Therapeutics Files Routine 8-K for Rule 425 Communications

TL;DR

**Edgewise Therapeutics filed a routine 8-K, no new news for traders.**

AI Summary

Edgewise Therapeutics, Inc. filed an 8-K on January 19, 2024, indicating that it is providing written communications pursuant to Rule 425 under the Securities Act. This filing is a routine disclosure and does not contain specific financial results or other major events. For investors, this filing primarily serves as a procedural update, confirming the company's compliance with SEC regulations regarding certain communications, but it doesn't reveal new information that would directly impact the stock price.

Why It Matters

This filing is a standard procedural update, indicating compliance with SEC communication rules, and does not contain new material information that would typically move the stock.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing and does not disclose any new risks or significant events for the company.

Analyst Insight

Investors should note this is a routine compliance filing and does not contain new material information that would warrant immediate action. Further research into other company disclosures would be necessary for investment decisions.

Key Players & Entities

• Edgewise Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 19, 2024 (date) — date of earliest event reported
• Rule 425 (other) — SEC rule for written communications under the Securities Act
• EWTX (other) — trading symbol for Edgewise Therapeutics, Inc.
• The Nasdaq Global Select Market (other) — exchange where Edgewise Therapeutics' common stock is registered

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share EWTX The Nasdaq
• $318.4 million — 1, 2023: The Company had approximately $318.4 million in cash, cash equivalents and marketabl

Filing Documents

• tm243583d3_8k.htm (8-K) — 36KB
• 0001104659-24-004966.txt ( ) — 207KB
• ewtx-20240119.xsd (EX-101.SCH) — 3KB
• ewtx-20240119_lab.xml (EX-101.LAB) — 33KB
• ewtx-20240119_pre.xml (EX-101.PRE) — 22KB
• tm243583d3_8k_htm.xml (XML) — 3KB

02 Results of Operations and Financial Conditions

Item 2.02 Results of Operations and Financial Conditions. The information set forth in Item 8.01 under the caption "Preliminary, Unaudited Financial Information" is incorporated into this Item 2.02 by reference.

01 Other Information

Item 8.01 Other Information. Preliminary, Unaudited Financial Information Based upon preliminary estimates and information available to Edgewise Therapeutics, Inc. (the Company) as of the date of this Current Report on Form 8-K, as of December 31, 2023: The Company had approximately $318.4 million in cash, cash equivalents and marketable securities. The Company had 70,453,342 shares of common stock outstanding. The Company's independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary, unaudited information and, accordingly, does not express an opinion or any other form of assurance about them. Anticipated 2024 Key Milestones The Company's 2024 anticipated key milestones are: Musculoskeletal Program – EDG-5506 Becker muscular dystrophy Report 24-month data from the open label ARCH trial in the first half of 2024. Continue to advance the Phase 2 CANYON placebo-controlled study, announce 1-year data in the fourth quarter of 2024. Announce Phase 2 DUNE (Becker, LGMD, McArdle) exercise challenge data in the first half of 2024. Duchenne muscular dystrophy Continue to advance Phase 2 LYNX trial, announce 3-month controlled dose-ranging data in the first half of 2024. Pending data from ongoing EDG-5506 studies, initiate Phase 3 trial in the second half of 2024. Cardiac Program – EDG-7500 Hypertrophic cardiomyopathy (HCM) Announce Phase 1 data in healthy volunteers and individuals with obstructive hypertrophic cardiomyopathy (oHCM) in the third quarter of 2024. Potential Market Opportunity The Company estimates that there are approximately 12,000 Becker patients and 35,000 Duchenne patients in the United States, Japan, France, Germany, Italy, Spain and the United Kingdom. The Company further estimates that HCM affects approximately one in 200-500 people in the United States, with a total U.S. patient population of approximately 900,000. Termination of ATM Prospectu

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDGEWISE THERAPEUTICS, INC. By: /s/ R. Michael Carruthers R. Michael Carruthers Chief Financial Officer Date: January 19, 2024

View Full Filing

View this 8-K filing on SEC EDGAR